A primary endpoint analysis of the NRG Oncology Phase III clinical trial NRG-GU003 comparing hypofractionated post-operative prostate bed radiotherapy (HYPORT) to the conventional post-prostatectomy radiotherapy (COPORT) for men with prostate cancer determined that treatment with HYPORT yielded no increase in patient-reported genitourinary (GU) or gastrointestinal (GI) toxicity for trial participants. However, the trial failed to reject the null hypothesis that dose-escalated radiation therapy (RT) was not superior to conventional RT. These results were presented during the Plenary Session of the American Society for Radiation Oncology’s (ASTRO) Annual Meeting in October 2021.